December 21, 2021
PAR-20-070 - Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33 - Clinical Trial Optional)
NOT-CA-22-002 - Notice of NCI's Participation in PAR-20-070, "Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33 - Clinical Trial Optional)"
National Cancer Institute (NCI)
The purpose of this Notice is to inform the extramural community that, effective immediately, NCI will participate in PAR-20-070, Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33 - Clinical Trial Optional).
NCI invites applications that propose to develop novel research infrastructure that will advance the science of cancer and aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities and up to 3 years of R33 support for expanded activities. Through this award, investigators will develop a sustainable research infrastructure to support projects that address critical interdisciplinary cancer and aging research questions.
Potential applicants are advised that applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s), convened by the National Institute on Aging (NIA) or the Center for Scientific Review (CSR) in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.
The following sections of PAR-20-070 have been revised:
A. Part 2. Full Text of Announcement, Section I. Funding Opportunity Description
NCI-specific information (only as shown below) to reflect NCI's participation in this funding opportunity announcement.
Phased Innovation Award
Currently reads:
Prior to the end of the R21 phase, awardees will submit a package that requests transition to the R33 phase. This package will include a progress report that describes progress towards each of the initial milestones and a clear description of how research during the R33 phase will be impacted by attainment of the R21 milestones. These materials will be reviewed by NIA program staff and then, if selected, the grant will be transitioned to an R33 award without the need to submit a new grant application. Decisions on transitioning to the R33 phase will be based on the original R21/R33 peer review recommendations, successful completion of the originally described milestones, program priorities, and availability of funds. If R21 awardees are not ready to submit an R33 transition package prior to the end of the R21 award, a no-cost extension for up to one year may be requested, during which time awardees may submit an R33 transition package. This one-year no-cost extension period will not count against the 5-year limit for the entire R21/R33 award.
Modified to read (in bold italics):
Prior to the end of the R21 phase, awardees will submit a package that requests transition to the R33 phase. This package will include a progress report that describes progress towards each of the initial milestones and a clear description of how research during the R33 phase will be impacted by attainment of the R21 milestones. These materials will be reviewed by NIA or NCI program staff and then, if selected, the grant will be transitioned to an R33 award without the need to submit a new grant application. Decisions on transitioning to the R33 phase will be based on the original R21/R33 peer review recommendations, successful completion of the originally described milestones, program priorities, and availability of funds. If R21 awardees are not ready to submit an R33 transition package prior to the end of the R21 award, a no-cost extension for up to one year may be requested, during which time awardees may submit an R33 transition package. This one-year no-cost extension period will not count against the 5-year limit for the entire R21/R33 award.
B. Part 2. Full Text of Announcement, Section V. Application Review Information
2. Review and Selection Process
Currently reads:
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s), convened by the National Institute on Aging in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.
Modified to read (in bold italics):
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s), convened by the National Institute on Aging or the Center for Scientific Review (CSR) in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.
C. Part 2. Section VII. Agency Contacts
Peer Review Contact(s)
Currently reads:
Ramesh Vemuri, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-496-9666
Email: [email protected]
Modified to read (in bold italics):
Examine your eRA Commons account for review assignment and contact information (information appears two weeks after the submission due date).
Financial/Grants Management Contact(s)
Currently reads:
Lesa McQueen, M.Sc.
National Institute on Aging (NIA)
Telephone: 301-402-7738
Email: [email protected]
Modified to read (in bold italics):
Lesa McQueen, M.Sc.
National Institute on Aging (NIA)
Telephone: 301-402-7738
Email: [email protected]
Crystal Wolfrey
National Cancer Institute (NCI)
Telephone: 240-276-6277
Email: [email protected]
All other aspects of PAR-20-070 remain unchanged.
Jennifer Guida, Ph.D., M.P.H.,
National Cancer Institute (NCI)
Telephone: 240-276-7634
Email: [email protected]
and Human Services (HHS)
